359 related articles for article (PubMed ID: 32882423)
21. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor efficacy of arginine modified amphiphilic nanoparticles co-delivering doxorubicin and iSur-pDNA via the multiple synergistic effect.
Song Y; Tang C; Yin C
Biomaterials; 2018 Jan; 150():1-13. PubMed ID: 29028548
[TBL] [Abstract][Full Text] [Related]
23. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
24. Dual-targeted delivery system using hollow silica nanoparticles with H
Mirzaei S; Khademi Z; Zolfaghari R; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Drug Dev Ind Pharm; 2023 Oct; 49(10):648-657. PubMed ID: 37772892
[TBL] [Abstract][Full Text] [Related]
25. Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer.
Shahriari M; Taghdisi SM; Abnous K; Ramezani M; Alibolandi M
J Control Release; 2021 Jul; 335():369-388. PubMed ID: 34058270
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antitumor efficacy of glutathione-responsive chitosan based nanoparticles through co-delivery of chemotherapeutics, genes, and immune agents.
Zhang L; Li Q; Chen J; Tang C; Yin C
Carbohydr Polym; 2021 Oct; 270():118384. PubMed ID: 34364626
[TBL] [Abstract][Full Text] [Related]
27. Chondroitin sulfate-functionalized polymeric nanoparticles for colon cancer-targeted chemotherapy.
Zu M; Ma L; Zhang X; Xie D; Kang Y; Xiao B
Colloids Surf B Biointerfaces; 2019 May; 177():399-406. PubMed ID: 30785037
[TBL] [Abstract][Full Text] [Related]
28. Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells.
Wani A; Savithra GHL; Abyad A; Kanvinde S; Li J; Brock S; Oupický D
Sci Rep; 2017 May; 7(1):2274. PubMed ID: 28536462
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antitumor efficacy of redox and pH dually responsive micelleplexes for co-delivery of camptothecin and genes.
Chen M; Zhang Y; Chen Z; Xie S; Luo X; Li X
Acta Biomater; 2017 Feb; 49():444-455. PubMed ID: 27940163
[TBL] [Abstract][Full Text] [Related]
30. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
[TBL] [Abstract][Full Text] [Related]
31. Targeted delivery of elesclomol using a magnetic mesoporous platform improves prostate cancer treatment both in vitro and in vivo.
Tarin M; Babaei M; Eshghi H; Matin MM; Saljooghi AS
Talanta; 2024 Apr; 270():125539. PubMed ID: 38141466
[TBL] [Abstract][Full Text] [Related]
32. MiRNA-204-5p and oxaliplatin-loaded silica nanoparticles for enhanced tumor suppression effect in CD44-overexpressed colon adenocarcinoma.
Yang H; Liu Y; Qiu Y; Ding M; Zhang Y
Int J Pharm; 2019 Jul; 566():585-593. PubMed ID: 31181310
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
[TBL] [Abstract][Full Text] [Related]
34. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary study on pH-sensitive lipid bilayer-coated mesoporous silica nanoparticles as a novel drug carrier for antitumor drug].
Li FF; Zhang XX; Guo SY; Gan Y; Li J
Yao Xue Xue Bao; 2013 Feb; 48(2):291-7. PubMed ID: 23672029
[TBL] [Abstract][Full Text] [Related]
36. Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21.
Khatami F; Matin MM; Danesh NM; Bahrami AR; Abnous K; Taghdisi SM
Carbohydr Polym; 2021 Aug; 266():118111. PubMed ID: 34044928
[TBL] [Abstract][Full Text] [Related]
37. Rod-shaped mesoporous silica nanoparticles for nanomedicine: recent progress and perspectives.
Cong VT; Gaus K; Tilley RD; Gooding JJ
Expert Opin Drug Deliv; 2018 Sep; 15(9):881-892. PubMed ID: 30173560
[TBL] [Abstract][Full Text] [Related]
38. Preparation of a mesoporous silica-based nano-vehicle for dual DOX/CPT pH-triggered delivery.
Llinàs MC; Martínez-Edo G; Cascante A; Porcar I; Borrós S; Sánchez-García D
Drug Deliv; 2018 Nov; 25(1):1137-1146. PubMed ID: 29779394
[TBL] [Abstract][Full Text] [Related]
39. Carrier-free nanoparticles of camptothecin prodrug for chemo-photothermal therapy: the making, in vitro and in vivo testing.
Ao M; Yu F; Li Y; Zhong M; Tang Y; Yang H; Wu X; Zhuang Y; Wang H; Sun X; Hong X; Chen XD
J Nanobiotechnology; 2021 Oct; 19(1):350. PubMed ID: 34717646
[TBL] [Abstract][Full Text] [Related]
40. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
